{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:34:03Z","timestamp":1793705643654,"version":"4.5.1"},"reference-count":30,"publisher":"Centers for Disease Control MMWR Office","issue":"46","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm7146a1","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T17:11:50Z","timestamp":1668705110000},"page":"1465-1470","source":"Crossref","is-referenced-by-count":20,"title":["Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2022"],"prefix":"10.15585","volume":"71","author":[{"given":"Elisabeth","family":"Krow-Lucal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Shepersky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Bahta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Loehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Dooling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R1","first-page":"1","article-title":"CDC. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","author":"McLean","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.15585\/mmwr.mm6701a7","article-title":"Recommendation of the Advisory Committee on Immunization Practices for use of a third dose of mumps virus\u2013containing vaccine in persons at increased risk for mumps during an outbreak.","volume":"67","author":"Marin","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R3","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/cid\/ciab979","article-title":"Maintenance of measles elimination status in the United States for 20 years despite increasing challenges.","volume":"75","author":"Mathis","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R4","unstructured":"Marlow M, Leung J, Marin M,  Mumps [Chapter 9]. In: Manual for the surveillance of vaccine-preventable diseases. Atlanta, GA: US Department of Human Services, CDC; 2021. https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/chpt09-mumps.pdf"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R5","unstructured":"Food and Drug Administration. Package insert: PRIORIX (measles, mumps, and rubella vaccine, live). Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2022. https:\/\/www.fda.gov\/media\/158941\/download"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R6","doi-asserted-by":"publisher","first-page":"S533","DOI":"10.1093\/infdis\/jir097","article-title":"Genetic characterization of measles vaccine strains.","volume":"204","author":"Bankamp","year":"2011","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R7","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.vaccine.2009.01.112","article-title":"Comparative analysis of the complete nucleotide sequences of measles, mumps, and rubella strain genomes contained in Priorix-Tetra and ProQuad live attenuated combined vaccines.","volume":"27","author":"Tillieux","year":"2009","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R8","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1080\/21645515.2017.1309486","article-title":"Two-year antibody persistence in children vaccinated at 12\u201315\u00a0months with a measles-mumps-rubella virus vaccine without human serum albumin.","volume":"13","author":"Berry","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/00365540110026593","article-title":"Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age.","volume":"33","author":"Gothefors","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R10","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1080\/21645515.2018.1502527","article-title":"Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study.","volume":"14","author":"MMR-162 Study Group","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/jpids\/piu081","article-title":"Safety and immunogenicity of human serum albumin-free MMR vaccine in US children aged 12\u201315 months.","volume":"4","author":"Mufson","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R12","doi-asserted-by":"crossref","unstructured":"Pietrantonj CD, Rivetti A, Marchione P, Debalini MG, Demicheli V. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev 2021;4:CD004407. 10.1002\/14651858.cd004407.pub4","DOI":"10.1002\/14651858.CD004407.pub5"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0140-6736(95)90471-9","article-title":"A new method for active surveillance of adverse events from diphtheria\/tetanus\/pertussis and measles\/mumps\/rubella vaccines.","volume":"345","author":"Farrington","year":"1995","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R14","doi-asserted-by":"crossref","first-page":"e687","DOI":"10.1542\/peds.2007-1578","article-title":"Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.","volume":"121","author":"France","year":"2008","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R15","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/aje\/kwk045","article-title":"Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom.","volume":"165","author":"Miller","year":"2007","journal-title":"Am J Epidemiol"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1542\/peds.2011-1111","article-title":"The risk of immune thrombocytopenic purpura after vaccination in children and adolescents.","volume":"129","author":"O\u2019Leary","year":"2012","journal-title":"Pediatrics"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.vaccine.2017.05.012","article-title":"Enhancing global vaccine pharmacovigilance: proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination.","volume":"36","author":"Perez-Vilar","year":"2018","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R18","doi-asserted-by":"publisher","first-page":"5781","DOI":"10.1016\/j.vaccine.2018.07.076","article-title":"Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12\u201315\u202fmonths: a phase III, randomized, non-inferiority trial.","volume":"36","author":"MMR-161 Study Group","year":"2018","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R19","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/jpids\/piz010","article-title":"Immunogenicity and safety of a measles-mumps-rubella vaccine administered as a first dose to children aged 12 to 15 months: a phase III, randomized, noninferiority, lot-to-lot consistency study.","volume":"9","author":"Klein","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R20","first-page":"282","article-title":"Global Advisory Committee on Vaccine Safety, 11\u201312 June 2003.","volume":"78","author":"World Health Organization","year":"2003","journal-title":"Wkly Epidemiol Rec"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R21","first-page":"2624","article-title":"Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7\u00a0years of age or older: a phase III, randomized study.","volume":"14","author":"Abu-Elyazeed","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R22","first-page":"511","article-title":"A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12\u201324 months of age.","volume":"30","author":"Gatchalian","year":"1999","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1201-9712(02)90112-8","article-title":"A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.","volume":"6","author":"Lee","year":"2002","journal-title":"Int J Infect Dis"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R24","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1442-200X.2010.03244.x","article-title":"Reappraisal of MMR vaccines currently used in Korea.","volume":"53","author":"Lee","year":"2011","journal-title":"Pediatr Int"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/BF02962367","article-title":"Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children.","volume":"26","author":"Usonis","year":"1998","journal-title":"Infection"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s15010-001-1098-7","article-title":"Neutralization activity and persistence of antibodies induced in response to vaccination with a novel mumps strain, RIT 4385.","volume":"29","author":"Usonis","year":"2001","journal-title":"Infection"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/00006454-199901000-00011","article-title":"Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.","volume":"18","author":"Usonis","year":"1999","journal-title":"Pediatr Infect Dis J"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R28","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1080\/21645515.2018.1554971","article-title":"A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration.","volume":"15","author":"MMR-158 Study Group","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R29","unstructured":"Food and Drug Administration. Package insert: M-M-R II (measles, mumps, and rubella virus vaccine live). Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2022. https:\/\/www.fda.gov\/media\/75191\/download"},{"key":"key-10.15585\/mmwr.mm7146a1-202211171209-R30","unstructured":"Kroger A, Bahta L, Hunter P. Timing and spacing of immunobiologics. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. Accessed August 1, 2022. https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/downloads\/general-recs.pdf"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T17:11:58Z","timestamp":1668705118000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7146a1.htm?s_cid=mm7146a1_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":30,"journal-issue":{"issue":"46","published-online":{"date-parts":[[2022,11,18]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm7146a1","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,18]]},"published":{"date-parts":[[2022,11,18]]}}}